Pre-made Mirvetuximab Soravtansine benchmark antibody (Whole mAb ADC, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Mirvetuximab Soravtansine benchmark antibody (Whole mAb ADC, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

ImmunoGen, Inc. (Nasdaq: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-914-1mg	1mg	Inquiry
GMP-Bios-INN-914-10mg	10mg	Inquiry
GMP-Bios-INN-914-100mg	100mg	Inquiry
GMP-Bios-INN-914-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Mirvetuximab Soravtansine Biosimilar, Whole Mab Adc, Anti-Folr1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody Drug Conjugate
INN Name	Mirvetuximab Soravtansine
Target	FOLR1
Format	Whole mAb ADC
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	ImmunoGen Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0